Tuesday, February 26, 2013

TearScience Looking to Make Its System Standard of Care for Dry Eye

TearScience, Inc., reportedly has secured up to $70 million in funding from HealthCare Royalty Partners to fully implement the company’s commercialization efforts and establish the TearScience system as the “Standard of Care” for evaporative dry eye. More than 23 million Americans suffer from dry eye disease. With the majority (86 percent2) suffering from evaporative dry eye, this represents a more than $10 billion market potential in North America. TearScience has launched the LipiView Ocular Surface Interferometer and the LipiFlow Thermal Pulsation System. The company says that LipiView measures the absolute thickness of the lipid layer of a dry eye patient’s tear film while LipiFlow treats the root cause of evaporative dry eye disease by unblocking obstructed Meibomian glands during an in-office procedure. The goal of treating evaporative dry eye by unblocking the Meibomian glands is to allow the glands to resume their natural production of lipids required for a healthy tear film and ocular surface. Read more.

No comments:

Post a Comment

Post a Comment